07:46 AM EDT, 10/09/2025 (MT Newswires) -- Astrazeneca ( AZN ) has partnered with Turbine to explore the use of the latter's simulation-based platform in developing antibody-drug conjugates, Turbine said Thursday.

The company said the collaboration would help predict treatment responses, reduce reliance on large-scale lab experiments, and better understand how and why cancer cells respond to or resist treatment.

Instead of testing hundreds of cell lines in the lab, the company said the platform will identify a smaller, targeted set for experiments and simulate responses across thousands of virtual models using AstraZeneca's ( AZN ) existing antibody-drug conjugate data.